About 960,574 shares traded.
AbbVie Inc. (ABBV) has an Analysts' Mean Recommendation of 2.4. It has underperformed by 32.98% the S&P500. Hamlin Capital Management Llc sold 25,904 shares as the company's stock declined 6.31% with the market. Looking at the stock's movement on the chart, AbbVie Inc. recorded a 52-week high of $125.86. Insiders sold a total of 211,197 shares of company stock worth $24,585,575 over the last 90 days. Laurel Grove Cap Limited Com has invested 1.46% in AbbVie Inc. (ABBV) escalated 0.4% and closed its last trading session at $94.65. A total of 7.38 million shares exchanged at hands and its average trading volume is standing at 7.33 million shares. It has outperformed by 27.65% the S&P500. Therefore 69% are positive.
Other equities analysts have also issued reports about the company. Evercore ISI reissued a "buy" rating and set a $144.00 price objective on shares of AbbVie in a report on Monday, January 29th. The firm earned "Buy" rating on Friday, September 15 by Jefferies.
Company's distance from 20 day simple moving average is -1.97% and distance from 50-Day simple moving average is -7.93%. (NYSE:RM). Brandywine Glob Investment Mgmt Ltd Liability Corporation reported 5,833 shares. The rating was maintained by Cowen & Co on Tuesday, September 5 with "Hold". Deutsche Bank has "Hold" rating and $63 target. Raymond James has "Outperform" rating and $82 target. The firm has "Buy" rating by Jefferies given on Friday, March 23. Zacks Investment Research lowered AbbVie from a "buy" rating to a "hold" rating in a report on Tuesday, March 20th.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. (NYSE:ABBV). Bank & Trust Of Montreal Can, a Ontario - Canada-based fund reported 5.40M shares. They expect $1.78 earnings per share, up 39.06 % or $0.50 from last year's $1.28 per share. BP's profit will be $2.17 billion for 15.36 P/E if the $0.66 EPS becomes a reality.
Investors sentiment decreased to 1.19 in Q4 2017. Its down 0.05, from 0.85 in 2017Q3. The hedge fund run by Beeneet Kothari held 273,977 shares of the business services company at the end of 2017Q4, valued at $47.24M, down from 294,577 at the end of the previous reported quarter. Orbis Allan Gray Ltd raised its position in shares of AbbVie by 35.7% during the 2nd quarter. Kelly Lawrence W & Associate Ca holds 26,345 shares. Boys Arnold And Inc reported 34,809 shares or 0.51% of all its holdings. Citigroup maintained salesforce.com, inc. That suggests something of the likelihood of a short squeeze in shares of ABBV. Schwab Charles Investment Mngmt Inc has 0% invested in Regional Management Corp. Verition Fund Management Ltd Liability holds 6,769 shares. Robeco Institutional Asset Mgmt Bv holds 1.17 million shares. Dorsey & Whitney Trust Ltd Liability holds 19,250 shares. Provise Management Group Incorporated Ltd stated it has 40,731 shares or 0.57% of all its holdings. This is an increase from AbbVie's previous quarterly dividend of $0.57. (NYSE:ABBV). 4,583 are held by Alphamark Advsrs Lc.
AbbVie Inc. (ABBV)'s RSI (Relative strength index) is at 27.07, its ATR (Average True Range) value is 4.3, while its Beta factor was calculated at 1.58. (NYSE:ABBV). Metropolitan Life Ins Commerce holds 315,606 shares.
Since October 30, 2017, it had 0 insider buys, and 12 insider sales for $49.35 million activity. Another trade for 4,294 shares valued at $512,853 was made by Michael Robert A. on Wednesday, February 28. (NYSE:ABBV) was sold by SALEKI-GERHARDT AZITA on Wednesday, February 28. 145,510 shares were sold by Schumacher Laura J, worth $14.07M. 18,300 shares were sold by Gosebruch Henry O, worth $1.66 million on Monday, October 30. GONZALEZ RICHARD A had sold 8,280 shares worth $976,084 on Wednesday, February 28. $14.07 million worth of AbbVie Inc. (NYSE:ABBV) was sold by ALBAN CARLOS on Wednesday, February 28. Second Curve Capital Llc who had been investing in Regional Mgmt Corp for a number of months, seems to be bullish on the $372.22M market cap company. Wesbanco Bankshares owns 33,097 shares. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. Therefore 80% are positive. The company now has a consensus rating of "Buy" and a consensus price target of $116.68. Salesforce.com had 230 analyst reports since August 21, 2015 according to SRatingsIntel. Tigress Financial maintained the stock with "Buy" rating in Thursday, November 30 report. The company was maintained on Thursday, January 4 by Jefferies. Bernstein upgraded the stock to "Outperform" rating in Thursday, September 10 report. Given the importance of identifying companies that will ensure earnings per share at a high rate, we later obsession to umpire how to determine which companies will achieve high amassing standards. (NYSE:ABBV) earned "Hold" rating by Leerink Swann on Thursday, March 22. The rating was downgraded by BMO Capital Markets on Friday, November 18 to "Market Perform". Barclays Capital maintained Clovis Oncology, Inc. Piper Jaffray reinitiated Clovis Oncology, Inc. The rating was downgraded by Credit Suisse on Monday, October 31 to "Neutral". The stock has "Hold" rating by RBC Capital Markets on Thursday, November 2. Moreover, World has 0.34% invested in AbbVie Inc. (NASDAQ:CLVS) to report earnings on May, 2. As a result, the company has Earnings per Share (EPS) growth of 16.11% for the coming year. BLOCK KEITH also sold $1.02 million worth of salesforce.com, inc. Ameriprise Financial Inc. raised its stake in AbbVie by 52.4% in the second quarter.